ReviewFrontiers in pharmacology2021

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors.

Xue-Lin Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.